PMC:7696151 / 23692-23949
Annnotations
LitCovid-PubTator
| Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
|---|---|---|---|---|---|
| 702 | 4-12 | Species | denotes | patients | Tax:9606 |
| 712 | 148-168 | Chemical | denotes | pegylated interferon | |
| 713 | 199-208 | Chemical | denotes | ribavirin | MESH:D012254 |
| 714 | 244-247 | Chemical | denotes | HCQ | MESH:D006886 |
LitCovid-sentences
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T166 | 0-257 | Sentence | denotes | All patients were randomized and divided into two groups; the control group treated with standard-of-care (SOC) consisted of 160 µg of subcutaneous pegylated interferon and 1000–12000 mg/day of oral ribavirin, and the group treated with 200 mg HCQ plus SOC. |